Abstract
Abstract Pulmonary edema induces local and systemic hypoxia in lungs and other tissues and organs, entailing the development of acute respiratory distress syndrome (ARDS). Hypoxia triggers a myriad of pathological responses, including angiogenesis and hyperpermeability of blood vessels in the lung and other tissues. Vascular endothelial growth factor, also named vascular permeability factor (VPF), is one of the key hypoxia-targeted genes. It is probably the most potent VPF in the body. In this article, I will discuss the possibilities and mechanistic insights of blocking the VEGF signaling pathway for treating acute pulmonary edema. In particular, anti-VEGF drugs for treating Covid-19-induced pulmonary edema will be discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
